Talazoparib actual price reference table after medical insurance reimbursement

Talazoparib (Talazoparib), as a targeted drug for breast cancer and other indications, has been marketed in China, but it has not been clearly included in the national medical insurance catalog, so the "national unified price after medical insurance reimbursement" does not currently exist. Hospital pharmacies in most areas will determine the selling price based on their own procurement channels, distribution policies, and regulations of the local medical insurance bureau. Therefore, patients should refer to the quotation from the local hospital pharmacy when actually purchasing drugs. Since they are not covered by medical insurance, domestic patients usually need to bear the full cost when purchasing medicines in hospitals. However, in some cities there may be local subsidies, charity assistance projects or commercial insurance reimbursement, which can appropriately reduce financial pressure.

Judging from the currently available market information, the price of the domestic version is more controllable than that of the overseas original research, but it is still a relatively expensive anti-tumor drug. The prices of the Hong Kong and European original drugs sold overseas are significantly higher. Among them, the latest price of 0.25mg30 is about 10,000 to 20,000 yuan, and the price of 1mg30 tablets is as high as 50,000 yuan, which puts a heavy financial burden. Since cross-border drug purchasing involves logistics, customs clearance and channel reliability issues, patients who consider purchasing from overseas should choose formal platforms to avoid purchasing products from informal sources.

In comparison, the price of the Laos generic version is more affordable. Its latest reference price is about 4,000 yuan for 1mg*30 tablets. The drug ingredients are consistent with the original research. It is an optional alternative for many patients with greater financial pressure. However, it needs to be reminded that although generic drugs are consistent in ingredients, their quality control system, production standards and marketing supervision are different from the new domestic drug review standards. Therefore, professional doctors should evaluate whether they are suitable before choosing, and ensure that they are purchased through formal channels to ensure quality and drug safety.

In general, whether talazoparib will be included in the medical insurance in the future still needs to wait for official updates. If it is successfully included in the medical insurance catalog, the actual amount paid by patients for purchasing drugs in domestic hospitals may drop significantly. Depending on the reimbursement ratio in different regions, the patient's out-of-pocket payment may even be reduced to the original 20%～40%. At the current stage when it is not yet covered by medical insurance, patients can discuss the choice of different versions of drugs with their attending doctor based on their own financial situation, and pay attention to various assistance or supplementary insurance policies to find the best balance between cost and treatment safety.

Reference materials:https://go.drugbank.com/drugs/DB11760